Others have suggested that HDAC inhibition potentiates cytotoxic chemotherapies by increasing double stranded breaks, precluded homologous repair and blocking the phosphotidylinositol 3-kinase (PI3K) pathway in in vitro ovarian cancer cells [57]. Here, HDAC9 is linked to ovarian carcinoma.